Status:
COMPLETED
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
AbbVie
Conditions:
Open-Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
Eligibility Criteria
Inclusion
- Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment
- Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months
Exclusion
- Current or anticipated enrollment in another investigational drug or device study
- Females who are pregnant, nursing, or planning a pregnancy during the study
Key Trial Info
Start Date :
June 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2022
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT04285580
Start Date
June 11 2020
End Date
May 14 2022
Last Update
June 8 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Trinity Research Group /ID# 232749
Dothan, Alabama, United States, 36301
2
The Eye Research Foundation /ID# 232694
Newport Beach, California, United States, 92663-3637
3
Coastal Research Associates /ID# 232798
Roswell, Georgia, United States, 30076
4
James D Branch MD /ID# 232718
Winston-Salem, North Carolina, United States, 27101